TY - JOUR
T1 - Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm
AU - Ruzilawati, A. B.
AU - Ab Wahab, Mohd Suhaimi
AU - Gan, S. H.
PY - 2010/2/1
Y1 - 2010/2/1
N2 - Objective: To estimate population pharmacokinetic parameters of repaglinide in 121 healthy Malaysian volunteers. Methods: Each subject received 4 mg of oral repaglinide. Six blood samples were taken per individual (0, 30, 60, 120, 180 and 240 min) for repaglinide's serum concentration determination by using high-performance liquid chromatography. The parametric Iterative Two-Stage Bayesian Population Model (it2b) program followed by the Non-Parametric Adaptive Grid (npag) program was used to determine a population pharmacokinetic modelling of repaglinide. Results: Using the npag program, the mean elimination rate constant (kel) of repaglinide was 0·58 ± 0·27 h and the volume of distribution (Vd) was 23·09 ± 9·19 Lh. Conclusion: In this first report, specifically on the population pharmacokinetic modelling of repaglinide, the data generated should help us to better understand appropriate dosage-regimens for the drug.
AB - Objective: To estimate population pharmacokinetic parameters of repaglinide in 121 healthy Malaysian volunteers. Methods: Each subject received 4 mg of oral repaglinide. Six blood samples were taken per individual (0, 30, 60, 120, 180 and 240 min) for repaglinide's serum concentration determination by using high-performance liquid chromatography. The parametric Iterative Two-Stage Bayesian Population Model (it2b) program followed by the Non-Parametric Adaptive Grid (npag) program was used to determine a population pharmacokinetic modelling of repaglinide. Results: Using the npag program, the mean elimination rate constant (kel) of repaglinide was 0·58 ± 0·27 h and the volume of distribution (Vd) was 23·09 ± 9·19 Lh. Conclusion: In this first report, specifically on the population pharmacokinetic modelling of repaglinide, the data generated should help us to better understand appropriate dosage-regimens for the drug.
KW - It2b
KW - Npag
KW - Population pharmacokinetic modelling
KW - Repaglinide
UR - http://www.scopus.com/inward/record.url?scp=74349099434&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2710.2009.01042.x
DO - 10.1111/j.1365-2710.2009.01042.x
M3 - Article
AN - SCOPUS:74349099434
SN - 0269-4727
VL - 35
SP - 105
EP - 112
JO - Journal of Clinical Pharmacy and Therapeutics
JF - Journal of Clinical Pharmacy and Therapeutics
IS - 1
ER -